Evogene annual return on equity
2016
2017
2018
2019
2020
2021
2022
2023
2024
Evogene Return on Equity (ROE) Growth & History (EVGN)
Evogene's return on equity was −340.58% for fiscal 2024.
View full Evogene company overviewEvogene annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2024 | 2024-12-31 | −340.58% | −210.75 pp |
| 2023 | 2023-12-31 | −129.83% | −56.66 pp |
| 2022 | 2022-12-31 | −73.16% | −12.09 pp |
| 2021 | 2021-12-31 | −61.07% | −6.59 pp |
| 2020 | 2020-12-31 | −54.49% | −16.33 pp |
| 2019 | 2019-12-31 | −38.15% | −3.30 pp |
| 2018 | 2018-12-31 | −34.85% | −8.25 pp |
| 2017 | 2017-12-31 | −26.60% | −6.09 pp |
| 2016 | 2016-12-31 | −20.51% | — |
Evogene quarterly return on equity
Q4.25
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q4 2025 | 2025-12-31 | −1,001.70% | — |
Evogene return on equity trends
Over the last five fiscal years, Evogene's return on equity decreased from −38.15% to −340.58%, a change of −302.42 percentage points. The latest reported quarter, Q4 2025, shows −1,001.70%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Evogene source filings ↗